It has been noted that orders are flowing regularly for the
consulting and outsourcing company
Accenture Plc.
(
ACN
). The company has regularly won orders; the recent addition is a
deal from The Phoenix Partnership ("TPP"). Accenture is required
to deploy patient administration system for the National Health
Services ("NHS") in southern England, across nine community
health systems.
The multi-million dollar agreement will see the collaboration
of Accenture and TPP to create a single electronic patient record
system. This deployment will help clinicians to assess and
exchange health information throughout the healthcare
community.
Accenture will partner the Trusts in Southern Community &
Child Health Procurement consortium for the implementation of the
TPP SystmOne solution. Additionally, Accenture will provide
support for integrating, hosting and deployment of the
applications for the solution.
Moreover, Accenture will also assist TPP in adding up
capabilities into the SystmOne platform such as e-prescribing, to
support community services, community hospitals, minor injury
management units and child health related issues.
Now the EHR is gaining ground across the globe and most of the
healthcare companies and medical organizations have been adopting
this new technology. Some of the government departments are
taking the help of Electronic medical records, in order to
rationalize health care costs, and help the doctors treat
patients efficiently.
Also, an interim survey by the outsourcing and consulting
services provider reveals that demand for Accenture's services
from some healthcare companies are increasing. We believe that
the opportunity will prove beneficial for Accenture's revenue
growth.
Though this is encouraging, we believe similar product
offerings from the likes of
Dell Inc
(
DELL
) and
International Business Machines Corp.
(
IBM
) are concerns.
Currently, Accenture has a Zacks #3 Rank (Hold).
ACCENTURE PLC (ACN): Free Stock Analysis
Report
DELL INC (DELL): Free Stock Analysis Report
INTL BUS MACH (IBM): Free Stock Analysis
Report
To read this article on Zacks.com click here.
Zacks Investment
Research